KromaTiD Announces Launch of New Product, dGH In-Site™

News provided by

Jun 09, 2020, 08:32 ET

LONGMONT, Colo., June 9, 2020 /PRNewswire/ -- KromaTiD, Inc. announced today the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert tracking assay. dGH In-Site™ enables researchers to directly measure the degree of DNA integration at a target while at the same time measuring off-target integration. In-Site provides a comprehensive high-specificity measurement of small DNA inserts that is not possible with any other method.

KromaTiD CEO, Christopher Tompkins, PhD, said of the in-Site platform: "We have always focused on providing custom dGH solutions to gene editing and pharmaceutical companies. dGH In-Site is the first of our standardized, genome-wide dGH products supporting the entire engineered cell markets. This is data that can help optimize your processes, understand the success of your edits and speed your engineered cell products to market."

By combining In-Site assays with other Targeted or De Novo dGH probes and paints, researchers can measure the distribution of inserts, profile structural variations and measure edit site rearrangements - all in the same test. As a single-cell technique, dGH in-Site measures complex, heterogeneous rearrangements and integration events, providing robust characterizations for a wide range of applications, including gene therapy, genome editing, cellular engineering, undiagnosed diseases and oncology. By combining In-Site assays with complementary and orthogonal techniques such as NGS, researchers can measure the complete range of outcomes of their edits, from the smallest indel to the largest structural rearrangement.

For more information regarding dGH in-Site™, reach out to [email protected].

About KromaTiD, Inc.

KromaTiD is transforming the fields of genome engineering, undiagnosed diseases and oncology through the discovery and characterization of structural genetic changes. KromaTiD offers a powerful suite of products and services for studying genomic rearrangements, custom assay development services and preclinical research support in the Company's GLP laboratory operations. KromaTiD's proprietary directional genomic hybridization platform (dGH^TM) has applications throughout genomics and provides direct, definitive data on structural variations that no other technology can provide. Today, KromaTiD's products and services are helping leading gene editing companies advance therapies to market. Learn more at www.kromatid.com or contact David Sebesta at 303-775-1512 or via email at [email protected].

SOURCE KromaTiD, Inc.